FXYD6 and prostate cancer: On the contrary, miR-372 functions as a tumor suppressor by targeting and binding to complementary sequences in the 3′-UTRs of genes, such as FXYD domain-containing ion transport regulator 6 (FXYD6), inhibiting growth and metastasis in different cancer cells, including osteosarcoma, renal cell carcinoma, prostate cancer, hepatocellular carcinoma, breast cancer, and cervical cancer cells [32].